<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112764">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02079766</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-1451-A07</org_study_id>
    <nct_id>NCT02079766</nct_id>
  </id_info>
  <brief_title>18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy</brief_title>
  <official_title>18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects With Repetitive Brain Trauma at High Risk for Chronic Traumatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the use of 18F-AV-1451 as a biomarker for chronic traumatic
      encephalopathy (CTE) and examine the relationship between clinical presentation and tau
      deposition.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>CTE Biomarker Analysis</measure>
    <time_frame>Up to 100 minutes post injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>18F-AV-1451 uptake and florbetapir F 18 standard uptake value ratio (SUVR) will be compared in subjects with a high risk of CTE and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship Between Clinical Presentation and Tau Deposition</measure>
    <time_frame>Up to 100 minutes post injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>The relationship among 18F-AV-1451 uptake, florbetapir SUVR, and measurements including neuropsychological assessment battery (NAB) List and Story Learning tests, Trail Making Test - Parts A and B, Wisconsin Card Sorting Test, Wechsler Adult Intelligence Scale - Revised (WAIS-R), Animal Fluency, NAB Naming Test, NAB Map Reading Test and Mini-Mental State Examination (MMSE).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Traumatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>High Risk of CTE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects at high risk of developing CTE (former National Football League players) will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of florbetapir F 18 and a single IV injection, 370 MBq (10 mCi) of 18F-AV-1451.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control subjects (former non-contact athletes) will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of florbetapir F 18 and a single IV injection, 370 MBq (10 mCi) of 18F-AV-1451.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>florbetapir F 18</intervention_name>
    <arm_group_label>High Risk of CTE</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Amyvid</other_name>
    <other_name>18F-AV-45</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-AV-1451</intervention_name>
    <arm_group_label>High Risk of CTE</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>T807</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects consented and currently enrolled in the Diagnosing and Evaluating
             Traumatic Encephalopathy Using Clinical Tests (DETECT) study protocol

          -  Can tolerate up to two PET imaging sessions

          -  Have the ability to provide informed consent for study procedures

        Exclusion Criteria:

          -  Claustrophobia

          -  Current clinically significant cardiovascular disease or clinically significant
             abnormalities on screening ECG

          -  History of risk factors for Torsades de Pointes or are taking drugs known to cause
             QT-prolongation

          -  Current clinically significant infectious disease, endocrine or metabolic disease,
             pulmonary, renal or hepatic impairment, or cancer that the investigator believes
             would affect study participation or scan results

          -  Have had a non-study related radiopharmaceutical imaging or treatment within 7 days
             prior to study PET imaging sessions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Chair</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avid Clinical Operations</last_name>
    <phone>215-298-0700</phone>
    <email>clinicaloperations@avidrp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Damage, Chronic</mesh_term>
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Brain Injury, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
